Inhaled trepostinil for severe fibrotic interstitial lung disease: grounds for cautious optimism?
- PMID: 34214474
- DOI: 10.1016/S2213-2600(21)00264-2
Inhaled trepostinil for severe fibrotic interstitial lung disease: grounds for cautious optimism?
Conflict of interest statement
SH has received grants from Boehringer Ingelheim, outside the submitted work. SH and AW have received speakers' fees and remuneration for membership of scientific advisory boards from Roche and Boehringer Ingelheim, outside the submitted work. AW has received remuneration for membership of scientific advisory boards from Veracyte, outside the submitted work.
Comment on
-
Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study.Lancet Respir Med. 2021 Nov;9(11):1266-1274. doi: 10.1016/S2213-2600(21)00165-X. Epub 2021 Jun 29. Lancet Respir Med. 2021. PMID: 34214475 Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical